FDA approves weight-loss drug to treat sleep apnea

The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the disorder affecting millions of Americans. 

On Friday, the federal agency green-lighted Eli Lilly’s Zepbound drug for the use, approving a prescription medicine suited for adults suffering from moderate to severe obstructive sleep apnea (OSA) and obesity. 

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” Dr.